New blood test could slash unnecessary antibiotics in sick newborns
NCT ID NCT03299751
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 2 times
Summary
This study tested whether a combination of 11 blood markers can more accurately diagnose late-onset sepsis in newborns in the NICU. Current methods are slow and often lead to unnecessary antibiotic use. Researchers enrolled 233 newborns with signs of infection to see if this biomarker panel could quickly rule out sepsis.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- biomarker combination (11 blood markers)
- What this could lead to
- If successful, this could provide a faster, more reliable way to rule out sepsis in newborns, reducing unnecessary antibiotic use and its complications.
- What could go wrong
- This is a completed diagnostic study, not a treatment trial. The biomarker combination may not prove accurate enough in real-world settings or for all newborns.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LATE ONSET NEONATAL SEPSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU de Nantes
Nantes, France
-
Hospices Civils de Lyon
Bron, 69500, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.